IL134754A - Interferon Consensus Compounds with N-terminal Pegilation and Methods - Google Patents

Interferon Consensus Compounds with N-terminal Pegilation and Methods

Info

Publication number
IL134754A
IL134754A IL134754A IL13475495A IL134754A IL 134754 A IL134754 A IL 134754A IL 134754 A IL134754 A IL 134754A IL 13475495 A IL13475495 A IL 13475495A IL 134754 A IL134754 A IL 134754A
Authority
IL
Israel
Prior art keywords
csf
consensus interferon
protein
pegylated
monopegylated
Prior art date
Application number
IL134754A
Other languages
English (en)
Hebrew (he)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23250903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL134754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL134754A publication Critical patent/IL134754A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL134754A 1994-10-12 1995-02-08 Interferon Consensus Compounds with N-terminal Pegilation and Methods IL134754A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/321,510 US5824784A (en) 1994-10-12 1994-10-12 N-terminally chemically modified protein compositions and methods

Publications (1)

Publication Number Publication Date
IL134754A true IL134754A (en) 2009-11-18

Family

ID=23250903

Family Applications (3)

Application Number Title Priority Date Filing Date
IL134754A IL134754A (en) 1994-10-12 1995-02-08 Interferon Consensus Compounds with N-terminal Pegilation and Methods
IL11258595A IL112585A (en) 1994-10-12 1995-02-08 N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them
IL13475400A IL134754A0 (en) 1994-10-12 2000-02-27 N-terminally chemically modified protein compositions and methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11258595A IL112585A (en) 1994-10-12 1995-02-08 N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them
IL13475400A IL134754A0 (en) 1994-10-12 2000-02-27 N-terminally chemically modified protein compositions and methods

Country Status (19)

Country Link
US (7) US5824784A (cg-RX-API-DMAC7.html)
EP (5) EP1564219A1 (cg-RX-API-DMAC7.html)
JP (8) JP3177251B2 (cg-RX-API-DMAC7.html)
KR (2) KR100248111B1 (cg-RX-API-DMAC7.html)
CN (4) CN101381409B (cg-RX-API-DMAC7.html)
AT (2) ATE179991T1 (cg-RX-API-DMAC7.html)
CA (3) CA2307142C (cg-RX-API-DMAC7.html)
DE (3) DE69509628T2 (cg-RX-API-DMAC7.html)
DK (1) DK0733067T3 (cg-RX-API-DMAC7.html)
ES (2) ES2224197T3 (cg-RX-API-DMAC7.html)
GR (1) GR3030526T3 (cg-RX-API-DMAC7.html)
IL (3) IL134754A (cg-RX-API-DMAC7.html)
LU (1) LU91006I2 (cg-RX-API-DMAC7.html)
MX (1) MX9602259A (cg-RX-API-DMAC7.html)
NL (1) NL300106I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ281469A (cg-RX-API-DMAC7.html)
PT (1) PT822199E (cg-RX-API-DMAC7.html)
WO (1) WO1996011953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA951008B (cg-RX-API-DMAC7.html)

Families Citing this family (563)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ES2159630T3 (es) * 1994-02-08 2001-10-16 Amgen Inc Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0788375A2 (en) * 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US6608183B1 (en) * 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
TR200101751T2 (tr) * 1998-04-28 2002-05-21 Applied Research Systems Ars Holding N.V. Poliol-IFN-beta konjugatları
MY129244A (en) * 1998-05-15 2007-03-30 Schering Corp Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
NL1009601C2 (nl) * 1998-07-09 2000-01-11 Univ Utrecht Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
EP1133563A2 (en) * 1998-07-16 2001-09-19 Hyseq, Inc. Methods and molecules relating to cd39-like polypeptides
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP2599503B1 (en) 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
CZ300762B6 (cs) 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ME00238B (me) 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR0008759B1 (pt) 1999-01-14 2014-03-11 Bolder Biotechnology Inc Métodos para a produção de proteinas contendo resíduos de cisteina livre
EP1369429A1 (en) * 1999-01-29 2003-12-10 F. Hoffmann-La Roche Ag GCSF conjugates
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
AU2824700A (en) * 1999-03-01 2000-09-21 Kyowa Hakko Kogyo Co. Ltd. Chemically modified g-csf preparations
US6485718B1 (en) * 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
NZ520261A (en) 2000-01-10 2003-10-31 Maxygen Holdings Ltd Granulocyte colony-stimulating factor PEG conjugates that exhibit an increased bioavailability and half-life in vivo and reduced side effects and immunogenicity
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7049761B2 (en) * 2000-02-11 2006-05-23 Altair Engineering, Inc. Light tube and power supply circuit
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2003530850A (ja) * 2000-04-14 2003-10-21 ユニバーシティー オブ サウス カロライナ リサーチ ファウンデーション 生物活性ヒスチジンアンモニアリアーゼのクローニング、過剰発現および治療用途
MXPA02010324A (es) 2000-04-21 2003-04-25 Amgen Inc Derivados de peptidos apo-ai/aii.
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
IL153785A0 (en) * 2000-07-12 2003-07-31 Gryphon Therapeutics Inc Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001273385B2 (en) * 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
ATE516820T1 (de) * 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
US20040082765A1 (en) * 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
CN1321134C (zh) * 2000-11-23 2007-06-13 赵剑 一种生物活性蛋白质的非均一制品及其制备方法
RU2275207C2 (ru) * 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
JP4656814B2 (ja) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
CN1514844A (zh) * 2001-02-06 2004-07-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰粒细胞集落刺激因子(g-csf)
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
CZ20032526A3 (cs) 2001-02-27 2003-12-17 Maxygen Aps Nové molekuly podobné interferonu beta
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
MXPA03010210A (es) 2001-05-11 2004-03-10 Amgen Inc Peptidos y moleculas relacionadas que se enlazan a tall-1.
CA2450985A1 (en) * 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
MXPA04003238A (es) * 2001-10-05 2004-07-08 Intermune Inc Metodo para tratar la infeccion de virus de hepatitis con una configuracion de suministro de interferon multifasica.
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
JPWO2003043651A1 (ja) * 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤
OA13063A (en) * 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
KR100480432B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
DE60323936D1 (de) * 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
EE05509B1 (et) * 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20060122106A1 (en) * 2002-06-14 2006-06-08 Amylin Pharmaceuticals, Inc Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003256613A1 (en) * 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
US8030459B2 (en) * 2002-07-19 2011-10-04 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
AU2003270454B2 (en) * 2002-09-09 2010-05-20 Nektar Therapeutics Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
MXPA05006945A (es) 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
EP1616003A4 (en) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7803362B2 (en) * 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
EP1603541B2 (en) 2003-03-05 2013-01-23 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
BRPI0408358A (pt) 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
MXPA05010411A (es) * 2003-03-28 2006-05-31 Biopolymed Inc Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen.
US20060134736A1 (en) * 2003-03-28 2006-06-22 Jacobs John W Human growth hormone conjugated with biocompatible polymer
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP1610825A2 (en) 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
BRPI0409322B8 (pt) * 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
ES2340494T3 (es) 2003-04-15 2010-06-04 Glaxosmithkline Llc Mutantes de sustitucion de il-18 humana y sus conjugados.
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
CA2533702C (en) 2003-07-22 2012-05-22 Nektar Therapeutics Al, Corporation Method for preparing functionalized polymers from polymer alcohols
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
PT1666496E (pt) * 2003-08-25 2014-06-24 Toray Industries Composto de interferão β
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0414017B8 (pt) 2003-09-17 2021-05-25 Nektar Therapeutics Al Corp pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
DE602004031645D1 (de) * 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
WO2005035727A2 (en) * 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
AU2004279895A1 (en) 2003-10-10 2005-04-21 Xencor, Inc Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
WO2005044836A2 (de) 2003-11-05 2005-05-19 Genovoxx Gmbh Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005053730A1 (ja) * 2003-12-05 2005-06-16 Kirin Beer Kabushiki Kaisha 末期心不全治療剤
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
WO2005070955A1 (en) * 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
US20050215710A1 (en) * 2004-03-23 2005-09-29 Gegg Colin V Jr Chemically modified protein compositions and methods
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
AU2005260664A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
GEP20115196B (en) 2004-08-19 2011-04-11 Biogen Idec Inc Neublastin variants
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
AU2005306894B2 (en) * 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
BRPI0519568C8 (pt) * 2004-12-22 2022-06-14 Ambrx Inc Aminoacil-trna sintetase (rs), composições que compreendem a dita aminoacil-trna sintetase, célula de levedura, célula fúngica, célula não eucariótica, vetor que codifica uma rs, polinucleotídeo e ainda método para produzir um polipeptídeo em uma célula com um aminoácido selecionado em uma posição especificada
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
EP1833993A4 (en) 2004-12-22 2009-07-22 Ambrx Inc HUMAN GROWTH HORMONE FORMULATIONS COMPRISING AN AMINO ACID CODED NON-NATURALLY
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CA2590462C (en) 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
BRPI0606934A2 (pt) 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
KR20070099013A (ko) * 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 면역 증강제
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
EP2314320A2 (en) 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CN101501068A (zh) 2005-05-18 2009-08-05 马克西根公司 改进的α-干扰素多肽
ATE500847T1 (de) * 2005-06-01 2011-03-15 Maxygen Inc Pegylierte g-csf-polypeptide und herstellungsverfahren dafür
US20060286657A1 (en) * 2005-06-01 2006-12-21 Samuel Zalipsky Novel bioconjugation reactions for acylating polyethylene glycol reagents
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20090221598A1 (en) 2005-06-17 2009-09-03 Kai Lin Use of Sanglifehrin in HCV
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
EP1926768B1 (en) 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
CN101208386B (zh) * 2005-08-02 2012-07-18 第一毛织株式会社 一种用于封装半导体设备的环氧树脂组合物
EP2099495A2 (en) * 2005-08-04 2009-09-16 Nektar Therapeutics AL, Corporation Conjugates of a g-csf moiety and a polymer
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP4829969B2 (ja) 2005-08-18 2011-12-07 アンブルックス，インコーポレイテッド ｔＲＮＡ組成物、およびその使用
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
DK3524261T5 (da) 2005-08-19 2024-09-02 Amylin Pharmaceuticals Llc Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
WO2007047303A2 (en) * 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1937294A4 (en) * 2005-10-21 2009-11-04 Synageva Biopharma Corp GLYCOLIC AND GLYCOSYLATED THERAPEUTIC PROTEINS DERIVED FROM POULTRY
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20090137736A1 (en) * 2005-11-08 2009-05-28 Ambrx, Inc. Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
EP1951890A4 (en) * 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
CN101448512B (zh) * 2005-12-14 2015-11-25 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
WO2007080942A1 (ja) 2006-01-12 2007-07-19 The Kitasato Institute インターフェロンαを含む口腔組成物
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
CN101420984B (zh) 2006-02-21 2013-01-02 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
WO2007115150A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Binding partners with immunoglobulin domains modified to have extended half-life
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2007133778A2 (en) * 2006-05-12 2007-11-22 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
US7851438B2 (en) 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008012525A1 (en) * 2006-07-25 2008-01-31 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
SI2054074T1 (sl) * 2006-08-04 2014-12-31 Prolong Pharmaceuticals Llc Modificiran eritropoetin
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0715754A2 (pt) * 2006-08-31 2013-07-09 Hoffmann La Roche mÉtodo para a produÇço de fator do crescimento similar Á insulina i
PT2061878E (pt) * 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
CN104193815A (zh) 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
MX2009003362A (es) 2006-09-28 2009-06-08 Schering Corp Uso de interleucina-10 pegilada para tratamiento de cancer.
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EA017770B1 (ru) 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
JP2008266219A (ja) * 2007-04-20 2008-11-06 National Institute Of Advanced Industrial & Technology リジン及びシステイン残基を含まないタンパク質
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
US20110159523A1 (en) * 2007-06-27 2011-06-30 Cedars-Sinai Medical Center N-terminal specific chemical labeling for proteomics applications
MX348799B (es) 2007-07-26 2017-06-29 Amgen Inc Enzimas aciltransferasa de lecitina-colesterol, modificadas.
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RS53404B (sr) 2007-08-27 2014-10-31 Ratiopharm Gmbh Tečna formulacija g-csf konjugata
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
JP5823125B2 (ja) 2007-10-23 2015-11-25 ウェルズ ファーゴ バンク ナショナル アソシエイション ヒドロキシアパタイト標的化多腕ポリマーならびに、このポリマーから作られるコンジュゲート
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
US20110124841A1 (en) * 2007-12-13 2011-05-26 Monthony James F Polypeptides Modified by Protein Trans-Splicing Technology
KR20160012252A (ko) 2007-12-27 2016-02-02 백스터 인터내셔널 인코포레이티드 생리학적으로 수용가능한 중합체 분자를 특이적으로 검출하기 위한 방법 및 조성물
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009120396A2 (en) * 2008-01-08 2009-10-01 The University Of California Compositions and methods for regulating erythropoientin expression and ameliorating anemia and stimulating erythropoiesis
US8128925B2 (en) 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
ES2523030T3 (es) * 2008-02-18 2014-11-20 Jiangsu Hengrui Medicine Co., Ltd. Un conjugado del G-CSF modificado por un polímero hidrosoluble
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2009121210A1 (zh) 2008-04-03 2009-10-08 厦门伯赛基因转录技术有限公司 双链聚乙二醇修饰的生长激素及其制备方法和应用
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
KR101647932B1 (ko) 2008-04-14 2016-08-11 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
GB0811743D0 (en) 2008-06-26 2008-07-30 Hemosol Biopharma Inc Composition
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
JP5698977B2 (ja) * 2008-07-30 2015-04-08 武田薬品工業株式会社 メタスチン誘導体およびその用途
US8273343B2 (en) * 2008-07-31 2012-09-25 Pharmaessentia Corp. Protein-polymer conjugates
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
JP5766118B2 (ja) 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
KR101732054B1 (ko) 2008-09-26 2017-05-02 암브룩스, 인코포레이티드 비천연 아미노산 복제 의존성 미생물 및 백신
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
CA2738064C (en) 2008-10-15 2013-03-19 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
JP5785872B2 (ja) 2008-10-17 2015-09-30 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 低度の水溶性ポリマーを含む改変血液因子
US8586710B2 (en) * 2008-10-20 2013-11-19 Usv, Ltd. Process for gram scale production of PEG-r-metHuG-CSF
EP2350658A2 (en) * 2008-10-21 2011-08-03 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
AU2009308909A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
IT1392655B1 (it) 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
DK2356467T3 (da) * 2008-12-11 2013-10-14 Baxter Int Påvisning af fysiologisk acceptable polymermolekyler under anvendelse af nær-infrarød spektroskopi
US8691205B2 (en) 2008-12-17 2014-04-08 Merck Sharp & Dohme Corporation Mono- and di-PEG IL-10 production; and uses
CA2757645C (en) 2009-04-06 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for delivering molecules
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
KR102033680B1 (ko) 2009-05-20 2019-10-18 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
MX2011014040A (es) 2009-06-19 2012-06-01 Medimmune Llc Variantes de la proteasa.
NZ597089A (en) 2009-06-25 2014-05-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2480578A4 (en) * 2009-09-25 2013-04-17 Vybion Inc MODIFICATION OF POLYPEPTIDE
WO2011050938A1 (de) 2009-10-26 2011-05-05 Genovoxx Gmbh Konjugate von nukleotiden und methoden zu deren anwendung
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
ES2639398T3 (es) * 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CN102234310B (zh) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
AU2011252990B2 (en) 2010-05-14 2017-04-20 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
AU2011256366C1 (en) 2010-05-17 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
EP2593130A2 (en) 2010-07-15 2013-05-22 Novo Nordisk A/S Stabilized factor viii variants
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN108285482A (zh) 2010-08-17 2018-07-17 阿姆布埃克斯股份有限公司 经修饰松弛素多肽及其用途
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
MX2013003903A (es) 2010-10-05 2013-05-20 Novartis Ag Nuevos tratamientos de infeccion por el virus de hepatitis c.
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN102453089B (zh) * 2010-10-25 2014-06-04 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CN103933577B (zh) * 2010-10-25 2014-12-10 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2643019B1 (en) 2010-11-24 2019-01-02 Lexicon Pharmaceuticals, Inc. Antibodies to notum pectinacetylesterase
MX2013006052A (es) 2010-11-30 2013-06-18 Novartis Ag Nuevos tratamientos de la infeccion por el virus de hepatitis c.
CN102485742A (zh) * 2010-12-02 2012-06-06 山东新时代药业有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
US10736969B2 (en) 2010-12-21 2020-08-11 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
HK1198173A1 (en) 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
EP2688584A4 (en) * 2011-03-25 2015-05-20 Univ Columbia PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM
US20140018289A1 (en) 2011-03-31 2014-01-16 Novartis Ag New treatments of Hepatitis C virus infection
BR112013024809A2 (pt) 2011-04-01 2016-09-06 Novartis Ag tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
CA2832829A1 (en) 2011-04-13 2012-10-18 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
RU2654231C2 (ru) 2011-06-28 2018-05-17 Алтернатив Инновейтив Текнолоджиз, Ллц Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты)
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
CN102952067A (zh) * 2011-08-30 2013-03-06 苏州欣诺科生物科技有限公司 用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
CN103826654A (zh) 2011-09-27 2014-05-28 诺华股份有限公司 用于治疗丙型肝炎病毒感染的阿拉泊韦
RU2014114849A (ru) 2011-10-14 2015-11-20 Алтернатив Инновейтив Текнолоджиз Ллц Устойчивые к деградации производные белков теплового шока-70 (бтш70) и способы их применения (варианты)
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2013063280A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
SI3130347T1 (sl) 2011-12-30 2020-02-28 Halozyme, Inc. Variante polipeptida PH20, formulacije in uporabe le-teh
CA2861402C (en) 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions
AU2013221317B2 (en) 2012-02-16 2017-07-06 Pangu Biopharma Limited Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
IN2014DN08236A (cg-RX-API-DMAC7.html) 2012-03-03 2015-05-15 Immungene Inc
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
HK1206610A1 (en) 2012-03-30 2016-01-15 Sorrento Therapeutics, Inc. Fully human antibodies that bind to vegfr2
BR112014024848A2 (pt) 2012-04-04 2017-07-11 Halozyme Inc terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2864358B1 (en) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
BR112015004022B1 (pt) 2012-08-31 2023-04-25 Sutro Biopharma, Inc Aminoácidos modificados compreendendo um grupo azido
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
CN103908660B (zh) * 2013-01-05 2015-02-04 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
CN103113466B (zh) * 2013-03-01 2015-06-03 中国科学院过程工程研究所 聚乙二醇修饰的重组人干扰素β-1b及制备方法
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
CN105792839A (zh) 2013-10-02 2016-07-20 诺华股份有限公司 用于治疗的胰岛素样生长因子拟似物
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3674314B8 (en) 2014-06-10 2023-07-12 Amgen Inc. Apelin polypeptides
PL3628680T3 (pl) 2014-06-12 2022-01-10 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
EP3485910A2 (en) 2014-08-22 2019-05-22 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
NZ730924A (en) 2014-11-06 2022-04-29 Pharmaessentia Corp Dosage regimen for pegylated interferon
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
CN104491843B (zh) * 2015-01-23 2017-09-12 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG‑CSF活性药物组合物
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
TWI849231B (zh) * 2015-03-03 2024-07-21 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-11之組合物及方法
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2016167291A1 (ja) 2015-04-13 2016-10-20 国立研究開発法人産業技術総合研究所 環状化サイトカイン及びその製法
EP3288577B1 (en) 2015-05-01 2021-10-27 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
CN108136006A (zh) 2015-08-06 2018-06-08 佐马美国有限公司 针对胰岛素受体的抗体片段和其治疗低血糖的用途
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
CA2997131C (en) 2015-09-18 2021-05-25 University Of Miyazaki Long-acting adrenomedullin derivative
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
US10935276B2 (en) 2015-10-20 2021-03-02 Steven Michalski Air mixing device
JP6855496B2 (ja) 2015-11-09 2021-04-07 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗ｃｄ２２抗体−メイタンシンコンジュゲートおよびその使用方法
PT3386531T (pt) 2015-12-08 2021-12-29 Biomarin Pharm Inc Uso de variantes do péptido natriurético tipo c para tratar a osteoartrite
WO2017105939A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
BR112018015480A2 (pt) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. proteínas de ligação ao antígeno que se ligam a pd-l1
US11208527B2 (en) 2016-04-15 2021-12-28 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
KR102020995B1 (ko) 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN119286279A (zh) 2017-12-26 2025-01-10 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
JP2021509805A (ja) 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 顆粒球コロニー刺激因子活性を示すポリペプチド
WO2019178374A1 (en) * 2018-03-14 2019-09-19 Ba Yong Pegylated antifreeze proteins and methods of making and using the same
CN119220109A (zh) 2018-03-30 2024-12-31 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
MA52347A (fr) 2018-04-24 2021-03-03 Amgen Inc Procédé de fabrication de compositions pharmaceutiques injectables
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
US20220162336A1 (en) 2018-07-22 2022-05-26 Bioasis Technologies, Inc. Treatment of lymphatic metastases
SMT202400087T1 (it) 2018-09-11 2024-03-13 Ambrx Inc Coniugati polipeptidici di interleuchina-2 e loro usi
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
CN113660957B (zh) 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
WO2020213015A1 (en) * 2019-04-15 2020-10-22 Nof Corporation Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
EP3955957A1 (en) 2019-04-15 2022-02-23 Qwixel Therapeutics LLC Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4121448A2 (en) 2020-03-20 2023-01-25 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US11602598B1 (en) 2020-08-27 2023-03-14 Fresenius Kabi Deutschland Gmbh Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
CN112710826A (zh) * 2020-11-17 2021-04-27 北京九强生物技术股份有限公司 一种提高试剂稳定性的包被和封闭方法
US11952461B2 (en) 2021-03-22 2024-04-09 Sunbio, Inc. Siloxy polyethylene glycol and derivatives thereof
EP4313163A1 (en) 2021-04-03 2024-02-07 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN113214328B (zh) * 2021-05-08 2022-06-28 宁波经济技术开发区弘翔生化科技有限公司 一种双水相体系以及基于双水相体系的单糖分离方法
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
US20250383357A1 (en) 2022-07-01 2025-12-18 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
CN120936679A (zh) 2023-03-17 2025-11-11 贝克曼库尔特有限公司 苯并噻吩并吡咯花菁染料
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2025230756A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
DE2047413C3 (de) 1970-09-26 1980-05-29 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Verfahren zur Herstellung von Peptiden in homogener Phase
US4002714A (en) * 1972-08-14 1977-01-11 Fumio Usui Method for producing a tapered pipe of reinforced synthetic resin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3139483C2 (de) 1981-10-03 1985-06-13 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Verfahren und Schaltungsanordnung zur Kontraststeigerung
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6142558A (ja) 1984-08-06 1986-03-01 Matsushita Electric Works Ltd アミノ樹脂成形材料
JPS62129298A (ja) 1985-12-02 1987-06-11 Chugai Pharmaceut Co Ltd 新規ポリペプチド
EP0215126B1 (en) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US5532341A (en) 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ES8800982A1 (es) 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62236497A (ja) 1985-09-17 1987-10-16 Chugai Pharmaceut Co Ltd 顆粒球コロニー刺激因子活性を有する糖蛋白質の製造方法
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
JPS63126900A (ja) 1986-06-26 1988-05-30 Takeda Chem Ind Ltd 化学修飾蛋白質
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
AU7675487A (en) 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
JPS6360938A (ja) 1986-09-02 1988-03-17 Meiji Milk Prod Co Ltd 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
JPH086063B2 (ja) 1987-07-22 1996-01-24 日本ペイント株式会社 親水性表面処理剤及び処理方法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
FI900178A0 (fi) * 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JPH04502011A (ja) 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO1990009798A1 (en) 1989-02-24 1990-09-07 Immunotherapeutics, Inc. Immobilized cytokines
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
JP2978187B2 (ja) 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
DE4009661C1 (cg-RX-API-DMAC7.html) 1990-03-26 1991-03-07 Aisa Automation Industrielle S.A., Vouvry, Ch
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
SG52537A1 (en) * 1990-10-17 1998-09-28 Amgen Inc Methods and compositions for the treatment of cell proliferation disorders
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
CH682636A5 (de) * 1990-12-21 1993-10-29 Bucher Guyer Ag Masch Verfahren zum selektiven Entfernen von Zucker aus Getränken.
EP0567566B2 (en) 1991-01-18 2007-07-04 Amgen Inc., Methods for treating tumor necrosis factor mediated diseases
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5197592A (en) * 1991-08-05 1993-03-30 Fmc Corporation Wire frame idler roll support
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
JP3235855B2 (ja) 1991-12-19 2001-12-04 住友製薬株式会社 細胞接着活性ペプチド及びその高分子修飾体
JP3387519B2 (ja) * 1992-03-04 2003-03-17 株式会社日立製作所 情報記録再生方式及びデイスク状記録媒体
FR2692736B1 (fr) 1992-06-23 1996-12-20 Thomson Csf Filtre radioelectrique de forte et moyenne puissance.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994012219A2 (en) 1992-11-25 1994-06-09 Amgen Boulder Inc. Modified insulin-like growth factors
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
US5481571A (en) 1993-11-12 1996-01-02 Pacific Communication Sciences, Inc. Method and apparatus for switching between radio frequency circuits
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
DE69503849T2 (de) * 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5661122A (en) 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
AU2601895A (en) 1994-05-24 1995-12-18 Amgen Boulder Inc. Modified insulin-like growth factors
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JP3708151B2 (ja) 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR101441331B1 (ko) 2013-07-19 2014-09-17 주식회사 슈프리마 광학식 지문 인식 장치

Also Published As

Publication number Publication date
JP2003155299A (ja) 2003-05-27
CA2178752C (en) 2000-10-17
US7090835B2 (en) 2006-08-15
JPH09506116A (ja) 1997-06-17
CN1896103A (zh) 2007-01-17
US5985265A (en) 1999-11-16
ES2224197T3 (es) 2005-03-01
JPH0925298A (ja) 1997-01-28
CN1313343A (zh) 2001-09-19
AU1841995A (en) 1996-05-06
ATE179991T1 (de) 1999-05-15
DE10299044I1 (de) 2003-03-27
JPH11310600A (ja) 1999-11-09
DK0733067T3 (da) 1999-11-01
IL112585A (en) 2000-08-31
JP2003327600A (ja) 2003-11-19
US5824784A (en) 1998-10-20
US20100310510A1 (en) 2010-12-09
US8258262B2 (en) 2012-09-04
CA2307142A1 (en) 1996-04-25
US20060233746A1 (en) 2006-10-19
EP0822199A2 (en) 1998-02-04
WO1996011953A1 (en) 1996-04-25
US20040181035A1 (en) 2004-09-16
KR100248111B1 (ko) 2000-03-15
CA2307142C (en) 2010-09-21
HK1008787A1 (en) 1999-05-21
EP0822199B1 (en) 2004-09-22
EP0733067A1 (en) 1996-09-25
JP2006045243A (ja) 2006-02-16
JP3177449B2 (ja) 2001-06-18
EP1564219A1 (en) 2005-08-17
US20120296072A1 (en) 2012-11-22
IL134754A0 (en) 2001-04-30
NZ281469A (en) 1997-04-24
ZA951008B (en) 1996-10-18
JP2010215657A (ja) 2010-09-30
JP5350330B2 (ja) 2013-11-27
ES2131811T3 (es) 1999-08-01
NL300106I2 (nl) 2003-02-03
DE69509628D1 (de) 1999-06-17
EP0733067B1 (en) 1999-05-12
JP3177251B2 (ja) 2001-06-18
DE69509628T2 (de) 1999-09-16
IL112585A0 (en) 1995-05-26
HK1008826A1 (en) 1999-05-21
EP2399930A1 (en) 2011-12-28
KR100261030B1 (en) 2000-06-15
PT822199E (pt) 2005-01-31
DE69533556T2 (de) 2005-10-20
ATE277078T1 (de) 2004-10-15
CN1139932A (zh) 1997-01-08
MX9602259A (es) 1997-02-28
CN1229388C (zh) 2005-11-30
EP0822199A3 (en) 2001-10-24
AU706700B2 (en) 1999-06-24
CN101381409B (zh) 2013-03-27
JP2006077021A (ja) 2006-03-23
DE69533556D1 (de) 2004-10-28
CN101381409A (zh) 2009-03-11
CN1071760C (zh) 2001-09-26
LU91006I2 (en) 2003-03-31
CA2178752A1 (en) 1996-04-25
GR3030526T3 (en) 1999-10-29
US20130189219A1 (en) 2013-07-25
CA2472085A1 (en) 1996-04-25
EP2392594A1 (en) 2011-12-07
NL300106I1 (nl) 2003-01-06
US7662933B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
CA2307142C (en) N-terminally chemically modified protein compositions and methods
US6956027B2 (en) N-terminally chemically modified protein compositions and methods
Gabriel et al. United States Patent (19)
AU741659B2 (en) N-terminally chemically modified protein compositions and methods
AU2004235682B2 (en) N-Terminally chemically modified protein compositions and methods
HK1008787B (en) N-terminally monopegylated polypeptides and process for their preparation
HK1078879A (en) N-terminally monopegylated polypeptides and process for their preparation
HK1008826B (en) N-terminally chemically modified protein compositions and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired